Antiepileptic Drugs: Potassium Channel Activators
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: GABAergic Pathway Potentiators
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jul 13, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
1Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
Novel emopamil-binding protein (EBP) inhibitors offer a new therapeutic approach. These compounds show promise for treating multiple sclerosis (MS) and related conditions.
Area of Science:
Background: